The University of Plymouth is offering a fully funded 3-year PhD studentship to support research into repurposing drugs for the treatment of B-cell lymphoma.
Diffuse large B-cell lymphoma (DLBCL) is one of the most common and aggressive subtypes of haematology malignancy. Standard first-line therapy (R-CHOP) cures many patients but ~40% are refractory or relapse. We use a hybrid of wet lab and dry lab techniques to repurpose drugs as adjunct therapies to R-CHOP.
Further project details are available on the university website via the url below.
Applicants should have a first or upper second-class honours degree (or equivalent) in an appropriate subject or a relevant Masters qualification. Experience with scripting languages and relational databases is desirable.
Application is via the university website.
www.plymouth.ac.uk/study/research-degrees/postgraduate-research-studentships/pharmacogenomic-repurposing-of-drugs-for-treatment-resistant-b-cell-lymphoma
Applications close midday April 11th 2026.